In a recent phase-II trial, tumor genomic profiles were evaluated using ctDNA for the administration of mutation-directed therapies; the mutations considered involved ESR1, HER-2, AKT1, P53, and phosphatase and tensin homolog deleted from chromosome 10 [23]. Here, AKT1 is linked to neoplasm.